SOURCE: Spencer Pharmaceutical Inc.

June 15, 2010 08:00 ET

Spencer Pharmaceutical Inc. Announces Dr. Mircea Alexandru Mateescu Joins the Scientific Advisory Board

BOSTON, MA--(Marketwire - June 15, 2010) -  Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announced today the addition of Dr. Mircea Alexandru Mateescu to head its Scientific Advisory Board. 

The management of Spencer Pharmaceutical Inc. is delighted to announce the addition of Dr. Mateescu as head of the Scientific Advisory Board. He brings a wealth of scientific research knowledge to the team. Dr. Mateescu is a research scientist and professor of biochemistry, with contributions (130 original articles, numerous book chapters and invited lectures) in different science domains such as drug delivery and biochemical pharmacology (cardioprotection and neuromodulation). He is also inventor or co-inventor of (25 patents) of several novel biomaterials with pharmaceutical and biomedical applications.

He is currently teaching and lecturing at the University of Quebec at Montreal (UQAM) where he oversees and collaborates with the Spencer's research team.

"Dr. Mircea Alexandru Mateescu has many years devoted to his field of research. Specializing in new formulations for efficient drug-delivery systems. He will be invaluable to the future long term growth and inevitable success of Spencer Pharmaceutical," stated Dr. Max Arella, President of Spencer Pharmaceutical Inc. "We are delighted to have Dr. Mateescu as an integral part of our organization," added Dr. Arella.

About Spencer Pharmaceutical Inc.

Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.

Important Information

About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.

Contact Information

  • Contact:

    Dr. Max Arella
    Spencer Pharmaceutical Inc.
    1+(617) 973-5017